ABCG2 and hyperuricemia: Our data showed that ABCG2 dysfunction was a strong independent risk for pediatric-onset hyperuricemia/gout: the MAF of p.Q141K was 38.7% compared to adult-onset with a MAF of 21.2%, compared to the normouricemic controls cohort with a MAF of 8.5%, and to the European population with a MAF of 9.4%.